17. Wolf DM, Yau C, Campbell MJ, et al. Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): evaluation of immune subtyping in the response predictive subtypes (RPS)...
BELLINI研究:具有肿瘤浸润淋巴细胞的早期TNBC新辅助双免联合治疗4周后,免疫活性增强 ESMO-Proffered Paper LBA13- Nivolumab and ipilimumab in early stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): first result...
WASHINGTON, DC — The proportion of patients with metastatic triple-negativebreast cancerwho respond to the immunotherapyatezolizumab(Tecentriq, Genentech) is only 10% to 13%, but the responses tend to last a long time, according to new results from an ongoing phase 1 study. The median duration...
参考资料: [1] Iván Pérez-Núñez et al. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nature Cancer(2022). [2] An mRNA therapy improves breast cancer response to immunotherapy in mice(来源:FierceBiotech)...
Wang K, Yang J, Wang B, et al. Expert consensus on the clinical application of immunotherapy in breast cancer: 2024. Translational Breast Cancer Research: A Journal Focusing on Translational Research in Breast Cancer, 2024, 5: 9. 关于特瑞普利单抗注射液(拓益®) ...
该方案达到了43.3%的客观缓解率(ORR),且对PD-L1阴性和多线治疗患者也有效,副作用相对较轻,该研究已在《癌症免疫治疗》(Journal for ImmunoTherapy of Cancer)上发表。并且研究中发现PD-L1表达水平并非有效的疗效预测指标,而肿瘤浸润淋巴细胞数量、治疗后CD8+T细胞的增加以及血液中某些细胞因子的变化可能是更好的预测...
“It also seems like TNBC is enriched [with] the types of breast cancers that are likely going to respond to immunotherapy. Many of these tumors tend to be under-infiltrated by immune cells and tend to be relatively bland immunologically,” said Soliman during a presentation at the 2018 OncLi...
Geurts V, Kok M. Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches. Curr Treat Options Oncol. 2023;24(6):628-643. doi:10.1007/s11864-023-01069-0 [6]Hsu JY, Chang CJ, Cheng JS. Survival, treatment regimens and medical costs of women newly ...
This research highlights the potential of dual-reprogramming of TIDCs and TAMs with the miR155 nanocomplexes as a promising strategy for TNBC immunotherapy, with potential for translation to other cancers with a similar microenvironment.doi:10.1016/j.ijbiomac.2023.126912Zhenghui Jing...
and many more approaches to target and harness the immune system. We need combination therapies and biomarkers. [Biomarkers] are very important in lung cancer. They are helping to guide which patients to treat with checkpoint inhibitors. In breast cancer, we don't yet have an [immunotherapy] ...